This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John F. Greden, MD; Rajiv Tandon, MD
Schizophrenia Program and Department of Psychiatry University of Michigan Medical Center Ann Arbor, MI 48109-0704

Arch Gen Psychiatry. 1995;52(3):197-200.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

MAJOR psychiatric disorders characteristically are lifetime in duration. Some, such as mood or panic disorders, tend to be episodic and recurrent; others, exemplified best by schizophreniatypically have more chronic, persistent courses punctuated with exacerbations. When confronted with long-term disorders, clinicians must consider a sequence of questions that pertain to long-term maintenance treatment: (1) What medications are available to help prevent relapse, and at what dosage must they be given to be efficacious? (2) What is the risk of relapse if long-term treatment is stopped, and how does this compare with the risk when treatment is sustained? (3) How severe are the risks or side effects associated with maintenance regimens? (4) Are there clinical or laboratory predictors that might foretell when a relapse might be expected so that risky treatments could be withheld until signs of impending relapse appear? (5) What are the safety, sideeffect, and financial cost-benefit ratios associated with . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?